Announcements
- LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- LAVA Announces Annual Meeting of Shareholders
- LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
- LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
- LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
- LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
- Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
More ▼
Key statistics
On Thursday, LAVA Therapeutics NV (4PKB:DEU) closed at 1.64, 56.19% above the 52 week low of 1.05 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.72 |
---|---|
High | 1.72 |
Low | 1.62 |
Bid | 1.64 |
Offer | 1.73 |
Previous close | 1.69 |
Average volume | 535.20 |
---|---|
Shares outstanding | 26.29m |
Free float | 18.74m |
P/E (TTM) | -- |
Market cap | 47.32m USD |
EPS (TTM) | -1.07 USD |
Data delayed at least 15 minutes, as of Jul 04 2024.
More ▼